(in thousands, except per share amounts and percentage data)
(unaudited)
Q1 2024
GAAP
Adjustments
Non-GAAP
Cost of sales
$
20,258
$
(5,523) (a)
$
14,735
Gross Margin
76.3%
6.5%
82.8%
Operating expenses:
Selling, general and administrative
$
61,975
$
(705)
(b)
$
61,270
Loss from operations
$
(39,066)
$
6,228
$
(32,838)
Net loss
$
(40,838)
$
6,228
(c)
$
(34,610)
Basic and diluted net loss per share
$
(0.82)
$
0.12
$
(0.70)
Q 1 2023
GAAP
Adjustment s
Non-GAAP
$
18,071
$
(5,523) (a)
$
12,548
75.5%
7.5%
83.0%
$
53,650
$
(705) (b)
$
52,945
$
(32,993)
$
6,228
$
(26,765)
$
(34,626)
$
6,228
(c)
$
(28,398)
$
(0.72)
$
0.13
$
(0.59)
Cost of sales adjustments related to the acquisition of Avedro, Inc. (Avedro) for amortization of developed technology intangible assets of $5.5 million in Q1 2024 and Q1 2023.
Avedro acquisition-related expenses for amortization expense of customer relationship intangible assets of $0.7 million in Q1 2024 and Q1 2023.
Includes total tax effect for non-GAAPpre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2024 and 2023.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Glaukos Corporation published this content on
01 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
02 May 2024 10:43:07 UTC.
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.